Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018526870> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2018526870 endingPage "138" @default.
- W2018526870 startingPage "114" @default.
- W2018526870 abstract "At the Hospital for Tropical Diseases, London, 417 patients suffering from intestinal amoebiasis have been treated and followed up under standard conditions. Emetine bismuth iodide was given in doses of 3 grains nightly for 10 nights to 220 patients. In 24 with E. histolytica trophozoites in the stool, this was preceded by 1 grain emetine by injection on 3 successive days. Of all these patients, 3 per cent. are known to have relapsed. The relapse rates :following treatment with chloramphenicol and aureomycin was so high that after short trials it was considered unjustifiable to continue the drugs. Of 14 patients followed up after treatment with oxytetracycline, two relapsed. Of 27 patients whose stools had contained E. histolytica cysts and who were followed up after treatment with fumagillin, one relapsed.Many toxic effects including dermatitis and albuminuria were encountered. Glaucarubin in doses of more than 4 mg. per kg. body weight was followed by a relapse rate of 12 per cent. among patients whose stools contained either E. histolytica cysts or trophozoites. A similar relapse rate followed the use of doses of 12 mg. or more dichloroacethydroxy-methylanilide in persons whose stools had contained E. histolytica cysts. It is concluded that emetine bismuth iodide is the most satisfactory drug at present available for the treatment of intestinal amoebiasis." @default.
- W2018526870 created "2016-06-24" @default.
- W2018526870 creator A5031046617 @default.
- W2018526870 creator A5064451049 @default.
- W2018526870 creator A5074788445 @default.
- W2018526870 date "1956-03-01" @default.
- W2018526870 modified "2023-09-25" @default.
- W2018526870 title "Symposium on the treatment of human amoebiasis II. The treatment of intestinal amoebiasis with emetine bismuth iodide, glaucarubin, dichloroacet-hydroxy-methylanilide, camoform and various antibiotics" @default.
- W2018526870 cites W1980848183 @default.
- W2018526870 cites W1985616821 @default.
- W2018526870 cites W2011931808 @default.
- W2018526870 cites W2026462575 @default.
- W2018526870 cites W2074297933 @default.
- W2018526870 cites W2320842474 @default.
- W2018526870 cites W2346057253 @default.
- W2018526870 cites W2413565330 @default.
- W2018526870 cites W2415214363 @default.
- W2018526870 doi "https://doi.org/10.1016/0035-9203(56)90074-8" @default.
- W2018526870 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/13324920" @default.
- W2018526870 hasPublicationYear "1956" @default.
- W2018526870 type Work @default.
- W2018526870 sameAs 2018526870 @default.
- W2018526870 citedByCount "18" @default.
- W2018526870 countsByYear W20185268702022 @default.
- W2018526870 crossrefType "journal-article" @default.
- W2018526870 hasAuthorship W2018526870A5031046617 @default.
- W2018526870 hasAuthorship W2018526870A5064451049 @default.
- W2018526870 hasAuthorship W2018526870A5074788445 @default.
- W2018526870 hasConcept C126322002 @default.
- W2018526870 hasConcept C203014093 @default.
- W2018526870 hasConcept C2776309324 @default.
- W2018526870 hasConcept C2776671240 @default.
- W2018526870 hasConcept C2776867272 @default.
- W2018526870 hasConcept C2778455923 @default.
- W2018526870 hasConcept C2778473333 @default.
- W2018526870 hasConcept C2778622654 @default.
- W2018526870 hasConcept C2780394083 @default.
- W2018526870 hasConcept C501593827 @default.
- W2018526870 hasConcept C71924100 @default.
- W2018526870 hasConcept C86803240 @default.
- W2018526870 hasConcept C89423630 @default.
- W2018526870 hasConcept C90924648 @default.
- W2018526870 hasConcept C98274493 @default.
- W2018526870 hasConceptScore W2018526870C126322002 @default.
- W2018526870 hasConceptScore W2018526870C203014093 @default.
- W2018526870 hasConceptScore W2018526870C2776309324 @default.
- W2018526870 hasConceptScore W2018526870C2776671240 @default.
- W2018526870 hasConceptScore W2018526870C2776867272 @default.
- W2018526870 hasConceptScore W2018526870C2778455923 @default.
- W2018526870 hasConceptScore W2018526870C2778473333 @default.
- W2018526870 hasConceptScore W2018526870C2778622654 @default.
- W2018526870 hasConceptScore W2018526870C2780394083 @default.
- W2018526870 hasConceptScore W2018526870C501593827 @default.
- W2018526870 hasConceptScore W2018526870C71924100 @default.
- W2018526870 hasConceptScore W2018526870C86803240 @default.
- W2018526870 hasConceptScore W2018526870C89423630 @default.
- W2018526870 hasConceptScore W2018526870C90924648 @default.
- W2018526870 hasConceptScore W2018526870C98274493 @default.
- W2018526870 hasIssue "2" @default.
- W2018526870 hasLocation W20185268701 @default.
- W2018526870 hasLocation W20185268702 @default.
- W2018526870 hasOpenAccess W2018526870 @default.
- W2018526870 hasPrimaryLocation W20185268701 @default.
- W2018526870 hasRelatedWork W1989967675 @default.
- W2018526870 hasRelatedWork W2037455648 @default.
- W2018526870 hasRelatedWork W2109267216 @default.
- W2018526870 hasRelatedWork W2122633332 @default.
- W2018526870 hasRelatedWork W2293013183 @default.
- W2018526870 hasRelatedWork W2330274991 @default.
- W2018526870 hasRelatedWork W2415385971 @default.
- W2018526870 hasRelatedWork W2418940933 @default.
- W2018526870 hasRelatedWork W2432904232 @default.
- W2018526870 hasRelatedWork W217093250 @default.
- W2018526870 hasVolume "50" @default.
- W2018526870 isParatext "false" @default.
- W2018526870 isRetracted "false" @default.
- W2018526870 magId "2018526870" @default.
- W2018526870 workType "article" @default.